Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
Metaplastic breast cancer (MBC) is a rare and aggressive subtype of breast cancer. Tumor characteristics typically feature estrogen receptor, progesterone receptor, and HER2-negative, triple-negative breast cancer (TNBC), with a poorer prognosis relative to pure invasive ductal or lobular disease. R...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2021-06-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/515510 |
| _version_ | 1818740533589180416 |
|---|---|
| author | Elan Gorshein Kant Matsuda Gregory Riedlinger Levi Sokol Lorna Rodriguez-Rodriguez Firas Eladoumikdachi Miral Grandhi Shridar Ganesan Deborah L. Toppmeyer Lindsay Potdevin Kathleen Toomey Kim M. Hirshfield Nancy Chan |
| author_facet | Elan Gorshein Kant Matsuda Gregory Riedlinger Levi Sokol Lorna Rodriguez-Rodriguez Firas Eladoumikdachi Miral Grandhi Shridar Ganesan Deborah L. Toppmeyer Lindsay Potdevin Kathleen Toomey Kim M. Hirshfield Nancy Chan |
| author_sort | Elan Gorshein |
| collection | DOAJ |
| description | Metaplastic breast cancer (MBC) is a rare and aggressive subtype of breast cancer. Tumor characteristics typically feature estrogen receptor, progesterone receptor, and HER2-negative, triple-negative breast cancer (TNBC), with a poorer prognosis relative to pure invasive ductal or lobular disease. Resistance to chemotherapy often leads to local recurrence and distant metastasis. Genomic profiling has identified multiple molecular abnormalities that may translate to targetable therapies in MBC. These tumors are known to display higher PD-L1 expressivity than other subtypes of breast cancer, and disease control with pembrolizumab and chemotherapy has been documented. We identify a patient with metastatic, metaplastic TNBC, with mesenchymal components and osseous differentiation, who completed 2 years of pembrolizumab treatment and has remained without evidence of disease after 32 months of observation, while maintaining good quality of life. Future efforts should focus on immunotherapy response with respect to the various subtypes of MBC, and treatment should continue to be incorporated in clinical trials to maximize disease response. |
| first_indexed | 2024-12-18T01:42:15Z |
| format | Article |
| id | doaj.art-bdb6ea84938e4385b44989b9ca95f57f |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-18T01:42:15Z |
| publishDate | 2021-06-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-bdb6ea84938e4385b44989b9ca95f57f2022-12-21T21:25:17ZengKarger PublishersCase Reports in Oncology1662-65752021-06-0114293193710.1159/000515510515510Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast CancerElan Gorshein0Kant Matsuda1Gregory Riedlinger2Levi Sokol3Lorna Rodriguez-Rodriguez4Firas Eladoumikdachi5Miral Grandhi6Shridar Ganesan7Deborah L. Toppmeyer8Lindsay Potdevin9Kathleen Toomey10Kim M. Hirshfield11Nancy Chan12Division of Medical Oncology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USADepartment of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USADepartment of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USADepartment of Radiology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USADepartment of Gynecologic Oncology, Rutgers Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USADivision of Surgical Oncology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USADivision of Surgical Oncology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USADivision of Medical Oncology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USADivision of Medical Oncology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USADivision of Surgical Oncology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USADivision of Medical Oncology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, Steeplechase Cancer Center, Somerville, NJ, USADivision of Medical Oncology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USADivision of Medical Oncology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USAMetaplastic breast cancer (MBC) is a rare and aggressive subtype of breast cancer. Tumor characteristics typically feature estrogen receptor, progesterone receptor, and HER2-negative, triple-negative breast cancer (TNBC), with a poorer prognosis relative to pure invasive ductal or lobular disease. Resistance to chemotherapy often leads to local recurrence and distant metastasis. Genomic profiling has identified multiple molecular abnormalities that may translate to targetable therapies in MBC. These tumors are known to display higher PD-L1 expressivity than other subtypes of breast cancer, and disease control with pembrolizumab and chemotherapy has been documented. We identify a patient with metastatic, metaplastic TNBC, with mesenchymal components and osseous differentiation, who completed 2 years of pembrolizumab treatment and has remained without evidence of disease after 32 months of observation, while maintaining good quality of life. Future efforts should focus on immunotherapy response with respect to the various subtypes of MBC, and treatment should continue to be incorporated in clinical trials to maximize disease response.https://www.karger.com/Article/FullText/515510metaplastic breast cancerexceptional responseimmunotherapyprogram death ligand-1 |
| spellingShingle | Elan Gorshein Kant Matsuda Gregory Riedlinger Levi Sokol Lorna Rodriguez-Rodriguez Firas Eladoumikdachi Miral Grandhi Shridar Ganesan Deborah L. Toppmeyer Lindsay Potdevin Kathleen Toomey Kim M. Hirshfield Nancy Chan Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer Case Reports in Oncology metaplastic breast cancer exceptional response immunotherapy program death ligand-1 |
| title | Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer |
| title_full | Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer |
| title_fullStr | Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer |
| title_full_unstemmed | Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer |
| title_short | Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer |
| title_sort | durable response to pd1 inhibitor pembrolizumab in a metastatic metaplastic breast cancer |
| topic | metaplastic breast cancer exceptional response immunotherapy program death ligand-1 |
| url | https://www.karger.com/Article/FullText/515510 |
| work_keys_str_mv | AT elangorshein durableresponsetopd1inhibitorpembrolizumabinametastaticmetaplasticbreastcancer AT kantmatsuda durableresponsetopd1inhibitorpembrolizumabinametastaticmetaplasticbreastcancer AT gregoryriedlinger durableresponsetopd1inhibitorpembrolizumabinametastaticmetaplasticbreastcancer AT levisokol durableresponsetopd1inhibitorpembrolizumabinametastaticmetaplasticbreastcancer AT lornarodriguezrodriguez durableresponsetopd1inhibitorpembrolizumabinametastaticmetaplasticbreastcancer AT firaseladoumikdachi durableresponsetopd1inhibitorpembrolizumabinametastaticmetaplasticbreastcancer AT miralgrandhi durableresponsetopd1inhibitorpembrolizumabinametastaticmetaplasticbreastcancer AT shridarganesan durableresponsetopd1inhibitorpembrolizumabinametastaticmetaplasticbreastcancer AT deborahltoppmeyer durableresponsetopd1inhibitorpembrolizumabinametastaticmetaplasticbreastcancer AT lindsaypotdevin durableresponsetopd1inhibitorpembrolizumabinametastaticmetaplasticbreastcancer AT kathleentoomey durableresponsetopd1inhibitorpembrolizumabinametastaticmetaplasticbreastcancer AT kimmhirshfield durableresponsetopd1inhibitorpembrolizumabinametastaticmetaplasticbreastcancer AT nancychan durableresponsetopd1inhibitorpembrolizumabinametastaticmetaplasticbreastcancer |